The Investment Heat Map: Where Capital’s Surging—and Where It’s Not

The biotech industry in the US is poised for recovery as IPOs and corporate dealmaking gain momentum in 2025, driven by renewed investor confidence and strategic activity within the sector. A combination of increased M&A interest, evolving investor preferences, and alternative capital-raising options highlights the resilience and adaptability of the industry. With geopolitical tensions overshadowing funding concerns and a focus on innovation, biotechs are positioned to seize new opportunities in both public and private markets. Join our panel of experts as they delve into the the key drivers behind the recent surge

Investor preferences are moving towards clinical-stage biotechs with robust Phase II data and strong leadership.

M&A activity and the patent cliff are driving public pharma interest in innovative private biotechs.

Venture capital and private financing show promising growth, offering alternatives to traditional IPOs.